The report reflects the agency’s activities in this transformational period across three core drivers: health, security and business. Preparing and launching the new agency, drove much of the work in the first half of the year. New products and services were developed, while a new brand image was unveiled, re-positioning the organisation from a monitoring centre to an agency empowered to act. While this preparatory work involved a significant, organisation-wide effort, core business activities continued. Key products included three digital-first flagship publications, namely the European Drug Report 2024 and additional modules of the European Responses Guide and the EUDA-Europol EU Drug Markets: In-depth analysis.

A total of 33 scientific and institutional publications were produced in the course of the year. The agency also authored or co-authored 16 scientific articles and book chapters published in prestigious journals and publications, which enhanced its scientific reputation. New analyses were released on priority policy and practice topics and areas, including the therapeutic use of psychedelic substances, harm reduction and the impact of economic recession on the use of illicit drugs. The agency also delivered two urgent Calls to action, on new synthetic opioids and on drug-related violence. Almost three million people visited the EUDA website in 2024 — a record number — and the upward trend in the number of social media followers and media requests continued.

Participation in drug-related events, training and capacity-building activities remained crucial for disseminating knowledge. In 2024, over 1 700 drug professionals benefitted from training organised by the EUDA, either alone or in cooperation with partners. Around 1 400 professionals also attended the eight EUDA webinars organised during the year.